<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16411">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893241</url>
  </required_header>
  <id_info>
    <org_study_id>TV48531-CV-40092</org_study_id>
    <nct_id>NCT02893241</nct_id>
  </id_info>
  <brief_title>Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting</brief_title>
  <official_title>Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting: a Multicenter, Prospective, Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ratiopharm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national, multicentre, prospective, open, two-arm, non-interventional study with
      hospitalized patients, who are treated routinely with cafedrine/theodrenaline or ephedrine
      after occurrence of perioperative hypotension, wherein the patients are assigned to a
      treatment arm based on the department.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of HR ≥ 100 beats/min</measure>
    <time_frame>during the first 15 minutes after initial drug administration of cafedrine/theodrenaline or ephedrine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted deviation below the individually determined, lowest systolic blood pressure BPmin</measure>
    <time_frame>within the first 15 minutes after the initial delivery of the antihypotonic drug as area1 (AUC) between the systolic blood pressure curve (below BPmin) and the lower limit BPmin</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1870</enrollment>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Patients, who undergo caesarean section under spinal anaesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cafedrine/theodrenaline</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine</intervention_name>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients, who are treated routinely with cafedrine/theodrenaline or ephedrine
        after occurrence of perioperative hypotension,
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatients, who received IV treatment (bolus administration) with
             cafedrine/theodrenaline or ephedrine (Ephedrin Meduna) due to an acute arterial
             hypotension

          -  Consent to use of data is available

          -  Patient under careful blood pressure and pulse monitoring (at least 2 minutes
             measuring interval (BP/HR) and/or at least 7 measurements within the first 15 minutes
             after the first application of cafedrine/theodrenaline or ephedrine)

        Cohort A:

          -  Treatment of hypotension in &lt; 100 mm Hg syst. and/or drop in blood pressure &gt; 20%
             syst. compared to preoperative base value (syst.)

          -  Patients ≥ 50 years old

          -  Pre-existing comorbidities (ASA classification 2-4)

          -  Elective surgery

          -  General anaesthesia with propofol/fentanyl ≥ 0.2 mg (or equivalent)

        Cohort B:

          -  Treatment of hypotension in &lt; 100 mm Hg syst. and/or drop in blood pressure &gt; 10%
             syst. compared to preoperative base value (syst.)

          -  Patients ≥ 18 years old

          -  Caesarean section under spinal anaesthesia

        Exclusion Criteria:

          -  Contraindication to the use of cafedrine/theodrenaline or ephedrine (Ephedrin Meduna)
             in accordance with current German specialist information

               -  Hypersensitivity to any product ingredient

               -  Hypertensive blood pressure readings

               -  Mitral stenosis

               -  Narrow-angle glaucoma

               -  Hyperthyroidism

               -  Pheochromocytoma

               -  Prostatic adenoma with urinary retention

               -  Bronchial asthmatics with sulphite sensitivity

               -  Hyper-excitability

               -  Arteriosclerosis

               -  Aneurysm

               -  Treatment with other indirect sympathomimetic drugs (Example:
                  phenylpropanolamine, phenylephrine, pseudoephedrine or methylphenidate)

               -  Use of Monoamine oxidase (MAO) inhibitors (including within the last two weeks)

          -  Prophylactic administration of cafedrine/theodrenaline or ephedrine or other
             anti-hypertensives

          -  Sepsis, septic shock or systemic inflammatory response syndrome (SIRS)

        Cohort A:

        • Intra-cranial surgery or heart surgery

        Cohort B:

          -  High-risk pregnancy (emergency Caesarean, severe infantile malformation)

          -  Multiple pregnancy

          -  Amniotic infection syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 133</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 122</name>
      <address>
        <city>Amberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 106</name>
      <address>
        <city>Aue</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 116</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 110</name>
      <address>
        <city>Bad Hersfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 134</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 121</name>
      <address>
        <city>Brake</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 119</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 111</name>
      <address>
        <city>Eichstätt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 107</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 131</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 114</name>
      <address>
        <city>Gelnhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 113</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 129</name>
      <address>
        <city>Heilbronn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 112</name>
      <address>
        <city>Herford</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 132</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 123</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 104</name>
      <address>
        <city>Kempen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 117</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 135</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 118</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 102</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 109</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 101</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 127</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 130</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 124</name>
      <address>
        <city>Neuruppin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 108</name>
      <address>
        <city>Pforzheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 136</name>
      <address>
        <city>Pirmasens</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 125</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 126</name>
      <address>
        <city>Solingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 128</name>
      <address>
        <city>Traunstein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 105</name>
      <address>
        <city>Warendorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 115</name>
      <address>
        <city>Wesel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 120</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 137</name>
      <address>
        <city>Worms</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 103</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 19, 2017</lastchanged_date>
  <firstreceived_date>September 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Theophylline</mesh_term>
    <mesh_term>Theodrenaline</mesh_term>
    <mesh_term>Cafedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
